Pharmaceutical Producers News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Pharma executives must sign self-declaration for UCPMP-2024 compliance by June 30, amid industry concerns on penalties.

India News: NPPA committee faces conflict as industry reps reform pricing rules. Activists criticize the DoP's composition. Will the industry influence drug prici

The government has expanded a committee to include more industry representation for reviewing drug and medical device pricing reforms. This move aims to ensure better availability of medicines and devices, while also providing incentives for industry growth and export sustainability. The committee will engage with industry experts and associations to evaluate pricing and availability issues. Ultimately, the government will make the final decisions, with the committee focusing on balancing pricing and availability of essential medicines and designing a price moderation framework for medical dev...

"We welcome the UCPMP. It is a balanced order that ensures that there is a healthy and ethical engagement between the pharmaceutical industry and medical professionals," Indian Drug Manufacturers' Association (IDMA) national president Viranchi Shah said. "It also brings clarity in the domain and has been updated as per current industry practices. The IDMA has always been in favour of ethical marketing practices for its members."

Ranjit Shahani, was an influential figure in Indian pharma,and former President of OPPI. With a mechanical engineering degree from IIT Kanpur and an MBA from JBIMS Bombay, Shahani held notable positions at ICI and Roche Products before joining Novartis in 1997.